Get more replies from employers
Send a job-specific resume in minutes.
Celcuity is seeking a Manager, FP&A to partner with R&D, Clinical Development, and Regulatory Affairs to drive strategic financial planning and insights. You will lead budgets, forecasts, and clinical trial spend analysis.
The role emphasizes building financial models, producing management reporting, and delivering actionable guidance to support growth and decision-making. Hybrid work options apply for local candidates.
This position is fully remote for those outside of the Minneapolis area and will be hybrid for local candidates.
Reporting to the Senior Director, Financial Planning & Analysis, the Manager, Financial Planning & Analysis (FP&A) partners closely with various functions including R&D, Clinical Development, Regulatory Affairs, Clinical Operations, Quality and Pharmaceutical Development to drive strategic business objectives through financial planning, analysis, and actionable insights. This role leads the planning, forecasting, and financial management of operating expenses, including support for clinical trial forecasting, monthly and quarterly variance analyses, and management reporting. The Manager develops financial models, performs strategic and ad-hoc analyses, and delivers actionable insights to inform decision-making. Acting as a trusted Finance partner, this position builds strong partnerships across the organization and helps drive decision-making to support the company's growth and strategic objectives.
Celcuity is a publicly traded commercial-stage biotechnology company developing targeted therapies for multiple solid tumor indications. The company's first FDA-approved product is REVTORPYK (gedatolisib), targets all class I isoforms of PI3K and the mTOR complexes to comprehensively block the PAM pathway. The PAM pathway is an important signaling pathway involved in many cancers and has historically been challenging to target.
A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR /HER2- locally advanced or metastatic breast cancer (\"ABC\"), supported FDA approval of REVTORPYK for use in patients without a *PIK3CA* mutation detected. Gedatolisib phase 3 clinical development programs are focused on the treatment of patients with HR /HER2- ABC in the 1L and 2L settings. A Phase 1b/2 clinical trial evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is on-going.
Celcuity is an Equal Opportunity Employer
Celcuity is committed to fair and equitable compensation practices, and we strive to provide employees with total compensation packages that are competitive. For this role, the anticipated base pay range is $140,000 - $155,000 DOE. The exact base pay offered for this role will depend on various factors, including but not limited to the candidate's geography, qualifications, skills, and experience.
The successful candidate will be eligible for an annual performance incentive bonus and a new hire equity package. Celcuity also offers various benefits offerings, including, but not limited to, medical, dental, vision insurance, 401(k) match, PTO, and paid holidays.